Trends in Hormonal Contraception

  • B. Runnebaum
  • T. Rabe
  • L. Kiesel
Conference paper


Oral hormonal contraceptives have been available since the early 1960s when Pincus and Rock found that norethynodrel (9.65 mg) in combination with mestranol (150 μg) inhibited ovulation and provided sufficient control of the menstrual cycle. Since then, different approaches to contraception have been pursued. Hormonal steroids can either act as ovulation inhibitors or prevent conception by altering the cervical mucus.


Menstrual Cycle Oral Contraceptive Contraceptive Method Hormonal Contraception Vaginal Ring 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. De Ligniers B, Basdevant A, Thomas G et al. (1986) Biological effect of estradiol 17β in postmenopausal women: oral versus percutaneous administration. J Clin Endocrinol Metab 62:536CrossRefGoogle Scholar
  2. Elkik F, Basdevant A, Jackanicz TM, Guy-Brand B, Mercier-Bodard C, Conard J, Bardin CW, Corvol P (1986) Contraception in hypertensive women using a vaginal ring delivering estradiol and levonorgestrel. J Clin Endocrinol Metab 63:29PubMedCrossRefGoogle Scholar
  3. Hahn DW, McGuire JL, Cohn RM, Beck LR, Tice TR, Lewis DH (1984) Development of microencapsulated norgestimate as a long-acting contraceptive. In: Zatuchni GI, Mishell DR, Shoupe D, Goldsmith A, Shelton JD, Sciarra J J (eds) Long-acting contraceptive delivery systems. Harper and Row, Philadelphia, pp 96–112Google Scholar
  4. Holst J, Cajander S, Carlstrom K, Damber MG, von Schoulz B (1983) Percutaneous oestrogen therapy opposed by lunestrenol or natural progesterone—effects on circulating oestrogens, FSH, sex hormone binding globulin and pregnancy zone protein. Maturitas 5:1–8PubMedCrossRefGoogle Scholar
  5. Juzpe AA (1984) Postcoital contraception. Clin Obstet and Gynaecol 11:787–797Google Scholar
  6. Laufer LR, De Fazzio JL, Lu JKH et al. (1983) Estrogen replacement therapy by transdermal estradiol administration. Am J Obstet Gynecol 146:533PubMedGoogle Scholar
  7. Rifkind BM, Segal P (1983) Lipid research clinics programm reference values for hyperlipidemia and hypolipidemia. J Am Med Ass 250:1869–1872CrossRefGoogle Scholar
  8. Lobo RA, March CM, Goebelsmann U et al. (1980) Subdermal estradiol pellets following hysterectomy and oophorectomy. Am J Obstet Gynecol 138:714PubMedGoogle Scholar
  9. Population Reports (1987) Injectables and implants. Popul Rep 3Google Scholar
  10. Shoupe D, Spitz I, Osborn C, Page MA, Mishell DR Jr, Lobo RA (1986) Effects of progesterone (P) antagonists on gonadotropins at midcycle and during the luteal phase. In: Society for gynecologic investigation, Toronto, Ontario, Canada, 19–22 March 1986, abstract 40Google Scholar
  11. Skouby SO (1987) Oral contraceptives and diabetes mellitus. Gynecol Endocrinol (Suppl) 2:30Google Scholar
  12. Stumpf PG, Maruca J, Santen RJ et al. (1982) Development of a vaginal ring for achieving physiologic levels of 17β estradiol in hypoestrogenic women. J Clin Endocrinol Metab 54:298CrossRefGoogle Scholar
  13. Van Santen MR (1987) Postcoital interception and contragestion. Elinkwijk, UtrechtGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1988

Authors and Affiliations

  • B. Runnebaum
    • 1
  • T. Rabe
    • 1
  • L. Kiesel
    • 1
  1. 1.Department of Obstetrics and Gynecology, Division of Gynecological Endocrinology, Women’s HospitalUniversity of HeidelbergHeidelbergGermany

Personalised recommendations